SpectraScience, Inc. (SCIE)
SpectraScience, Inc. operates in the Medical - Specialties industry of the Healthcare sector, headquartered in San Diego, MN, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $4,924. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -86737.9%. Its beta of -30.43 implies it has historically moved less than the broad market.
SpectraScience, Inc. specializes in creating and distributing an advanced technological platform designed for the immediate classification of tissue as normal, pre-cancerous, or cancerous, thereby bypassing the requirement for invasive physical biopsies. This innovative approach is accessible in the United States, Europe, and other global regions. The company's product line includes the WavSTAT3 optical biopsy system, which assesses colon tissue for normal, pre-cancerous, or cancerous conditions without surgical removal. Another key offering is the WavSTAT4 optical biopsy system, a diagnostic tool for the colon that employs UV laser light to optically scan and analyze tissue, enabling physicians to make instant diagnoses during endoscopic cancer screenings. Additionally, SpectraScience provides related accessories such as mobile consoles and disposable forceps. The company is also actively developing an application for esophageal diagnostics, focused on identifying pre-cancerous and cancerous tissue formations. Founded in 1983, the company operated as GV Medical, Inc. until it adopted the name SpectraScience, Inc. in October 1992, and is headquartered in San Diego, California.
SpectraScience, Inc. is most often compared with the following Healthcare names: